Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache
- PMID: 32583902
- DOI: 10.1111/head.13889
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache
Abstract
Background: The otic ganglion (OG) provides parasympathetic innervation to the cerebral circulation and cranial structures and may be involved in the pathophysiology of trigeminal autonomic headaches. This structure has never been targeted in any headache disorder.
Objective: To investigate the safety of injecting onabotulinumtoxin A (BTA) toward the OG in 10 patients with intractable chronic cluster headache and to collect efficacy data.
Methods: A total of 10 patients with chronic cluster headache were enrolled in this open-label, multi-dose pilot safety study. All patients were recruited and treated on an out-patient basis at St Olav's University Hospital (Norway). In 5 patients each, the OG was the injection target with 12.5 IU of BTA or 25 IU, respectively. The primary outcome measure was adverse events (AEs) and the main secondary outcome was the number of attacks per week measured at baseline and in the second month following injection.
Results: For the primary endpoint, we analyzed data for all 10 patients. There were a total of 17 AEs in 6 of the 10 patients. All AEs were considered mild and disappeared by the end of follow-up. The median number of attacks per week at baseline was 17.0 [7.8 to 25.8] vs 14.0 [7.3 to 20.0] in the second month following injection; difference: 3 (95%CI: -0.3 to 7.9), P = .063.
Conclusions: Injection with BTA toward the OG appears to be safe. We did not find a statistically significant reduction in the number of attacks per week at month 2 after injection compared to the baseline. This study suggests that the OG is not an important target for the treatment of chronic cluster headache. A future study employing more precise targeting of the OG may be indicated.
Keywords: botulinum toxin; chronic cluster headache; otic ganglion; pterygopalatine ganglion; sphenopalatine ganglion; trigeminal autonomic cephalalgia.
© 2020 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
Similar articles
-
Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.Headache. 2019 Sep;59(8):1229-1239. doi: 10.1111/head.13608. Epub 2019 Jul 25. Headache. 2019. PMID: 31342515 Free PMC article. Clinical Trial.
-
Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache.Cephalalgia. 2016 May;36(6):503-9. doi: 10.1177/0333102415597891. Epub 2015 Jul 31. Cephalalgia. 2016. PMID: 26232105 Free PMC article. Clinical Trial.
-
Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine.Cephalalgia. 2017 Apr;37(4):356-364. doi: 10.1177/0333102416648328. Epub 2016 May 6. Cephalalgia. 2017. PMID: 27154997 Free PMC article. Clinical Trial.
-
The Efficacy of Botulinum Toxin in Cluster Headache: A Systematic Review.J Oral Facial Pain Headache. 2020 Spring;34(2):129–134. doi: 10.11607/ofph.2444. Epub 2019 Sep 27. J Oral Facial Pain Headache. 2020. PMID: 31560734
-
OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation.Expert Opin Drug Saf. 2021 Nov;20(11):1275-1289. doi: 10.1080/14740338.2021.1948531. Epub 2021 Jul 5. Expert Opin Drug Saf. 2021. PMID: 34187265 Review.
Cited by
-
The profile of refractory chronic cluster headache.Neurol Sci. 2025 Jan;46(1):295-302. doi: 10.1007/s10072-024-07708-0. Epub 2024 Jul 24. Neurol Sci. 2025. PMID: 39044103
-
Drug Treatment of Cluster Headache.Drugs. 2022 Jan;82(1):33-42. doi: 10.1007/s40265-021-01658-z. Epub 2021 Dec 17. Drugs. 2022. PMID: 34919214 Free PMC article. Review.
-
Current and Novel Therapies for Cluster Headache: A Narrative Review.Pain Ther. 2025 Feb;14(1):1-19. doi: 10.1007/s40122-024-00674-7. Epub 2024 Nov 3. Pain Ther. 2025. PMID: 39489854 Free PMC article. Review.
-
Cluster headache in adults.Aust Prescr. 2022 Feb;45(1):15-20. doi: 10.18773/austprescr.2022.004. Epub 2022 Feb 1. Aust Prescr. 2022. PMID: 35233134 Free PMC article. Review.
-
[Clinical use of botulinum toxin type A in pain medicine].Schmerz. 2023 Aug;37(4):297-307. doi: 10.1007/s00482-023-00730-9. Epub 2023 Jun 26. Schmerz. 2023. PMID: 37365293 German.
References
-
- Crespi J, Bratbak D, Dodick DW, et al. Anatomical landmarks for localizing the otic ganglion: A possible new treatment target for headache disorders. Cephalalgia Rep. 2019;2:1-7.
-
- Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: A meta-analysis of population-based studies. Cephalalgia. 2008;28:614-618.
-
- Leone M, Cecchini AP, Mea E, Tullo V, Bussone G. Epidemiology of fixed unilateral headaches. Cephalalgia. 2008;28(Suppl. 1):8-11.
-
- Jensen RM, Lyngberg A, Jensen RH. Burden of cluster headache. Cephalalgia. 2007;27:535-541.
-
- Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not during direct dural activation of trigeminal afferents. Headache. 2009;49:1131-1143.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous